Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials
暂无分享,去创建一个
A. Kirtane | S. Bangalore | David O. Williams | D. Cutlip | R. Byrne | F. Feit | N. Amoroso | Sunil K. Kumar | J. Slater | Mario V. Fusaro | Mario V Fusaro
[1] Y. Hayashi,et al. Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) , 2012, Circulation.
[2] J. W. Louwerenburg,et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. , 2012, Journal of the American College of Cardiology.
[3] H. Bøtker,et al. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). , 2011, The American journal of cardiology.
[4] I. Seong,et al. Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial , 2011, Circulation.
[5] P. Serruys,et al. Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus , 2011, Circulation.
[6] Gregg W Stone,et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.
[7] P. Fitzgerald,et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary , 2011, JACC. Cardiovascular interventions.
[8] G. Condorelli,et al. Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial: A Randomized Comparison of 3 Drug-Eluting Stents in Diabetic Patients , 2011, Circulation. Cardiovascular interventions.
[9] G. Stone,et al. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial , 2011, Circulation. Cardiovascular interventions.
[10] I. Seong,et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. , 2011, JACC. Cardiovascular interventions.
[11] M. Nazzaro,et al. Successful management of ostial left main thrombus by systemic thrombolysis. , 2011, European heart journal.
[12] A. Kastrati,et al. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials , 2011, Clinical Research in Cardiology.
[13] S. Chae,et al. Comparison of three‐year clinical outcomes between sirolimus‐versus paclitaxel‐eluting stents in diabetic patients: Prospective randomized multicenter trial , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[15] A. Kastrati,et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. , 2010, Journal of the American College of Cardiology.
[16] P. Fitzgerald,et al. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. , 2009, JACC. Cardiovascular interventions.
[17] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.
[18] A. Kastrati,et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. , 2009, Journal of the American College of Cardiology.
[19] G. Stone,et al. Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial , 2009, Circulation.
[20] H. Bøtker,et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. , 2009, The American journal of cardiology.
[21] M. Buchbinder,et al. A randomized comparison of sirolimus‐eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: The DECODE study , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[22] A. Kastrati,et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. , 2008, European heart journal.
[23] M. Pfisterer,et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis , 2008, BMJ : British Medical Journal.
[24] I. Seong,et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. , 2008, Journal of the American College of Cardiology.
[25] F. Varbella,et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). , 2008, The American journal of cardiology.
[26] S. Chae,et al. Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. , 2008, Journal of interventional cardiology.
[27] F. Eberli,et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. , 2008, European heart journal.
[28] H. Drexler,et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. , 2007, Journal of the American College of Cardiology.
[29] Arianna Azzellino,et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). , 2007, Journal of the American College of Cardiology.
[30] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[31] P. Serruys,et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[32] J. Tardif,et al. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. , 2007, Journal of the American College of Cardiology.
[33] P. Serruys,et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. , 2006, European heart journal.
[34] I. Seong,et al. Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease , 2006, Circulation.
[35] P. Serruys,et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[36] J. Tijssen,et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. , 2006, The New England journal of medicine.
[37] E. Bramucci,et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.
[38] P. Fitzgerald,et al. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial , 2006, Circulation.
[39] I. Iakovou,et al. Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. , 2006, The American journal of cardiology.
[40] P. Serruys,et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. , 2006, JAMA.
[41] H. Bøtker,et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. , 2006, Journal of the American College of Cardiology.
[42] P. Buser,et al. Incremental Cost-Effectiveness of Drug-Eluting Stents Compared With a Third-Generation Bare-Metal Stent in a Real-World Setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) , 2005 .
[43] J. Popma,et al. Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice , 2005, Circulation.
[44] E. Bramucci,et al. Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy). , 2005, The American journal of cardiology.
[45] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[46] F. Fernández‐Avilés,et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.
[47] Gregg W Stone,et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.
[48] A. Kastrati,et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.
[49] F. Eberli,et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.
[50] P. Serruys,et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). , 2005, American Journal of Cardiology.
[51] A. Kastrati,et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. , 2005, European heart journal.
[52] G. Stone,et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. , 2005, Journal of the American College of Cardiology.
[53] J. Stauffer,et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. , 2005, Journal of the American College of Cardiology.
[54] A. Kastrati,et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.
[55] V. Legrand,et al. Drug-eluting stents: meta-analysis in diabetic patients. , 2004, European heart journal.
[56] A. Scheen,et al. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. , 2004, Diabetes care.
[57] W. O’Neill,et al. Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy , 2004, Circulation.
[58] David L. Brown,et al. Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4,284 cases. , 2004, Diabetes care.
[59] R. T. Hurst,et al. Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management , 2003, Annals of Internal Medicine.
[60] William Wijns,et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.
[61] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.
[62] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[63] J. Killian,et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. , 2002, Journal of the American College of Cardiology.
[64] D. Glogar,et al. Mechanism of lumen gain during coronary stentdeployment in diabetic patients compared withnon-diabetic patients , 2002, Coronary artery disease.
[65] I. Olkin,et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.
[66] M. Leon,et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.
[67] D. Faxon,et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.
[68] James T. Willerson,et al. Appointment of New Associate Editor for Circulation , 1996 .
[69] Robert L. Frye,et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.
[70] T. Christensen,et al. Increased Arterial Wall Stiffness and Thickness in Medium-Sized Arteries in Patients with Insulin-Dependent Diabetes Mellitus , 1988, Acta radiologica.
[71] D. Faxon,et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. , 1988, The New England journal of medicine.
[72] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[73] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. , 2013, European heart journal.
[74] A. Kaltoft,et al. Impact of Diabetes on Clinical Outcomes after Revascularization with Everolimus- and Sirolimus-Eluting Stents , 2011 .
[75] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[76] Jonathan J Deeks,et al. metan-an alternative meta-analysis command , 1999 .
[77] J. Willerson. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, Circulation.